Zacks Investment Research
31 Jul 2026, 22:46 UTC · 1h ago
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
31 Jul 2026, 22:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Adma Biologics (ADMA) currently possesses a Zacks Rank of #5 (Strong Sell). — A 'Strong Sell' rating from a major research provider typically signals negative sentiment and potential downward price pressure.
-0.60The Zacks Consensus EPS estimate for Adma Biologics has decreased by 2.03% over the past month. — Downward revisions in earnings estimates generally indicate deteriorating fundamental outlooks, which often leads to price declines.
-0.40Adma Biologics is trading at a Forward P/E of 10.79, which is a significant discount compared to its industry average of 20.65. — A deep valuation discount can attract value investors, though it may also reflect the market's lack of confidence in the company's growth.
+0.20Continue reading
6 related stories
Search tags
Adma Biologics is expected to report earnings on August 5, 2026, with a predicted EPS of $0.16 and revenue of $125.77 million. — The projected growth is modest (3-6%), making this a neutral catalyst until the actual results are compared against these benchmarks.
+0.10Which stocks this story touches
The company has a Zacks Rank of #5 (Strong Sell), and its stock price is underperforming the S&P 500 and its sector.
The company is listed as having significant page view growth.
The company is listed as having significant page view growth.
The company is listed as having significant page view growth.
The company is listed as having significant page view growth.
The company is listed as having significant page view growth.
The company is listed as having significant page view growth.
The company is listed as having significant page view growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
59m ago
